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Retroperitoneal Metastases
in Testicular Cancer: Role of
CT Measurements of Residual
Masses in Decision Making for
Resection after Chemotherapy1
PURPOSE: To determine the relative importance of computed tomographic (CT)
measurements for the prediction of histologic findings in residual masses in patients
with nonseminomatous testicular cancer.
MATERIALS AND METHODS: Measurements of the maximum transverse size of
retroperitoneal metastases before and after chemotherapy were available in 641
patients who underwent resection after chemotherapy while their levels of tumor
markers were normal. Radiologic measurements of mass size and clinical characteris-
tics (histologic findings in primary tumor and levels of a-fetoprotein, human
chorionic gonadotropin, and lactate dehydrogenase before chemotherapy) were
related to histologic findings in the residual mass with logistic regression analysis.
RESULTS: At resection, 302 patients had benign tissue, and 339 had residual tumor
(mature teratomas or cancer). Tumor was more frequent in larger masses after
chemotherapy but was unrelated to mass size before chemotherapy. Inclusion of the
reduction in size significantly improved the logistic regression model, which
included mass size after chemotherapy. This model was further improved with the
addition of clinical characteristics. Areas under the receiver operating characteristic
curves increased from 0.74 to 0.77 and 0.83 with these models.
CONCLUSION: A small retroperitoneal mass after chemotherapy is an important
predictor of benign histologic findings in residual masses in patients with nonsemino-
matous testicular cancer. However, better predictions can be made when the
reduction in size and clinical characteristics are considered as well. Decisions
regarding resection should be based on the combination of these characteristics
rather than on only mass size after chemotherapy.
Computed tomographic (CT) evaluations are important in patients with testicular cancer.
At presentation, abdominal and thoracic imaging is performed to determine the extent of
disease. Patients with metastatic disease are candidates for combination chemotherapy
with cisplatin, which leads to a long-term survival of about 80% (1,2). Repeat CT scans are
obtained to monitor the effect of treatment, which is apparent from a reduction in mass
size (3). After chemotherapy, the presence of a residual mass on a CT scan may guide the
decision to perform resection. The most frequent procedures are laparotomy with
retroperitoneal lymph node dissection for residual retroperitoneal metastases and thora-
cotomy with wedge resection for residual lung nodules (2).
When retroperitoneal metastases are not detectable as residual masses on abdominal CT
scans obtained after chemotherapy, a resection is usually not performed (2,4). This decision
is based on the notion that residual tumor (mature teratoma or viable cancer) is rare in very
small (eg, ,10-mm) remnants of initial disease and that resection of only necrotic and/or
fibrotic remnants has no therapeutic benefit (5).
In addition to the radiologic characteristics, clinical characteristics have been related to
the presence of malignancy. These include histologic findings in the primary tumor
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(presence of teratomatous elements) and
levels of tumor markers before chemother-
apy, namely, elevated levels of a-fetopro-
tein (AFP), elevated levels of human cho-
rionic gonadotropin (HCG), and normal
levels of lactate dehydrogenase (LDH)
(6–10).
In this study, we analyzed the relative
importance of the radiologic and clinical
characteristics for the prediction of the
histologic findings at retroperitoneal re-
section. We combined radiologic and
clinical characteristics in multivariable
statistical models. We further examined
how these multivariable combinations
may serve to improve decision making in
the treatment of individual patients.
MATERIALS AND METHODS
Patients
We included patients who were treated
with chemotherapy for metastatic non-
seminomatous testicular cancer and who
underwent resection of retroperitoneal
lymph nodes after induction chemother-
apy. To obtain a more homogeneous group
of patients, we excluded patients who
underwent resection after relapse and pa-
tients with elevated levels of tumor mark-
ers AFP or HCG at the time of surgery,
extragonadal primary tumors, or histo-
logically pure seminoma without ele-
vated levels of serum tumor markers be-
fore chemotherapy.
Data were available in 716 patients.
This data set consisted of data in 544
patients who were previously examined
to derive a prediction model for the histo-
logic findings in the residual masses (11)
and data in 172 patients to validate this
model (12). For the present analysis, we
excluded 75 patients for whom measure-
ments of mass size before (n 5 52) or after
(n 5 65) chemotherapy were missing;
therefore, data in 641 patients were avail-
able for analysis (Table 1). Patients were
treated at the Klinikum Grosshadern, Mu-
nich, Germany (n 5 98 [13]); Memorial
Sloan-Kettering Cancer Center, New York,
NY (n 5 88 [8]); Norwegian Radium Hos-
pital, Oslo (n 5 150 [9]); and a number of
university hospitals in the Netherlands
(Groningen, n 5 154; other centers, n 5
151 [7,14,15]).
Most patients were treated in the 1980s
(median year 1986; year range, 1979–
1996). Chemotherapeutic treatment was
usually in the context of randomized
clinical trials; details have been reported
elsewhere (8,9,12–15). Data collection was
a. b.
Figure 1. CT images show a left paraaortic mass (arrows) with a maximum transverse diameter of
(a) 50 mm before chemotherapy and (b) 15 mm after chemotherapy. The residual mass contained
fibrosis and some remnants of mature teratoma.
TABLE 1
Characteristics of 641 Patients
with Testicular Cancer
Characteristic n (%)
Hospital
Klinikum Grosshadern
(Munich, Germany) 98 (15)
Memorial Sloan-Kettering
Cancer Center (New York,
NY) 88 (14)
Norwegian Radium Hospital
(Oslo, Norway) 150 (23)
University hospitals* (the
Netherlands) 151 (24)
University hospital (Gro-
ningen, the Netherlands) 154 (24)
Year of treatment
Before 1985 256 (40)
1985–1989 226 (35)
1990 or after 159 (25)
Histologic findings at retroperi-
toneal resection
Necrosis 302 (47)
Mature teratoma 268 (42)
Cancer 71 (11)
Note.—All patients were treated with chemo-
therapy for metastatic nonseminomatous tes-
ticular cancer and had normal levels of tumor
markers AFP and HCG at the time of retroperi-
toneal lymph node resection.
* Amsterdam Free University (n 5 18),
Leiden (n 5 50), Nijmegen (n 5 33), Rotter-
dam Cancer Institute (n 5 37), Rotterdam
Dijkzigt Hospital (n 5 13).
TABLE 2
Radiologic Measurements and Histologic Findings at Resection
Characteristic
Necrosis
(n 5 302)
Teratoma
(n 5 268)
Cancer
(n 5 71)
Total
(N 5 641)
Size before chemotherapy (mm)
0–29 75 (52) 60 (41) 10 (7) 145
30–49 90 (51) 73 (42) 13 (7) 176
50–99 93 (44) 89 (42) 32 (15) 214
$100 44 (42) 46 (43) 16 (15) 106
Size after chemotherapy (mm)
0–9 90 (73) 28 (23) 6 (5) 124
10–19 99 (63) 53 (34) 6 (4) 158
20–29 60 (50) 46 (38) 15 (12) 121
30–49 29 (28) 53 (51) 23 (22) 105
$50 24 (18) 88 (66) 21 (16) 133
Reduction in size (%)
$85 75 (80) 16 (17) 3 (3) 94
70–84 67 (64) 27 (26) 11 (11) 105
50–69 99 (54) 62 (34) 23 (13) 184
30–49 36 (43) 37 (45) 10 (12) 83
0–29 25 (20) 82 (66) 17 (14) 124
,0* 0 (0) 44 (86) 7 (14) 51
Note.—Numbers in parentheses are percentages.
* Increase in size.
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prospective at all participating centers.
Before and after chemotherapy, abdomi-
nal CT scans were obtained and inter-
preted by the local radiologist at each
participating institution. At all centers,
patients were candidates for resection of
retroperitoneal lymph nodes if residual
masses were depicted on CT scans ob-
tained after chemotherapy; this criterion
implied resection of masses equal to or
larger than approximately 10 mm. At the
University Hospital Groningen, resection
was also performed when the primary
tumor contained teratomatous elements,
even if no residual masses were detectable
(7). At the Norwegian Radium Hospital,
resection was routinely performed regard-
less of the size of the mass after chemo-
therapy (9).
Radiologic and Clinical
Characteristics
Radiologic characteristics considered in
this study were the maximum transverse
diameter (in millimeters) of the mass
before and after chemotherapy. In prin-
ciple, these measurements were read from
the CT scans (Fig 1). When a CT scan was
considered to be completely normal (no
mass depicted), a mass size of 2 mm was
assumed for statistical analysis. This pro-
cedure improved the statistical distribu-
tion of mass size.
Clinical characteristics included histo-
logic findings in the primary tumor (tera-
toma-positive or teratoma-negative) and
levels of tumor markers AFP, HCG, and
LDH before chemotherapy. These charac-
teristics were considered on the basis of
their predictive value for the histologic
content of the residual mass in previous
studies. These four characteristics were
combined in one predictor, simple score,
in which all four characteristics were given
equal weight.
The histologic outcome of retroperito-
neal resection was classified according to
the worst histologic finding present, that
is, cancer (n 5 71), mature teratoma (n 5
268), or necrosis (n 5 302). Immature
teratoma was classified as cancer because
of its more severe prognostic conse-
quence compared with that of mature
teratoma (16).
Statistical Analysis
Logistic regression analysis was used to
relate the finding of necrosis or tumor
(mature teratoma or viable cancer) at
resection to the radiologic and clinical
characteristics. We first performed univari-
able analyses of the following radiologic
characteristics: size before chemotherapy,
size after chemotherapy, and reduction in
size. Reduction in size was calculated as
follows: (size before chemotherapy 2 size
after chemotherapy) 4 size before chemo-
therapy. These characteristics were catego-
rized for descriptive analyses by using
clinically relevant cutoff values.
For further statistical analysis, these
characteristics were considered as con-
tinuous variables. Since the relationship
between these variables and the histo-
logic findings in the residual mass did not
necessarily have to be linear, restricted
cubic spline functions with five knots
were used in the logistic regression mod-
els (17,18). These flexible and smooth
functions can take many forms, while the
continuous character of the variable is
maintained. Further, spline functions are
used to test for nonlinearity on the log-
a. b.
Figure 2. Graphs depict the relationships between the probability of
finding necrosis at resection and the radiologic characteristics of (a) mass
size before chemotherapy, (b) mass size after chemotherapy, and (c) re-
duction in mass diameter. Solid and dotted lines indicate the point
estimates and 95% CIs, respectively, with a flexible nonlinear function (a
spline). Dashed line indicates use of the linear term (size before chemother-
apy and reduction) or the square root of a transformed variable (square
root of the size after chemotherapy) in the logistic regression model,
which provided an adequate fit.
c.
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odds scale. When statistically significant
nonlinearity was observed (P , .05), a
simple transformation (square, square
root, or logarithm) was performed with
the continuous variable, and the nonlin-
earity of the transformed variable was
tested again.
Three logistic regression models were
constructed and compared by using re-
ceiver operating characteristic (ROC)
analysis (19). The first model included only
measurements of mass size after chemother-
apy. The second model included informa-
tion about size before and after chemother-
apy. The third model included the clinical
characteristics in addition to radiologic mea-
surements toevaluate theirpredictivecontri-
bution. Interaction terms between covari-
ables were studied to test for violation of
the additivity assumption (18).
In general, an evaluation of model per-
formance may be too optimistic when
the performance is determined with the
same data set used to estimate the model
(18,20). To correct for this bias, resam-
pling methods have been advocated, such
as the bootstrap method (21). We obtained
areas under the ROC curves with 200
bootstrap samples consisting of 641 pa-
tients that were drawn with replacement
from the original data set. Goodness of fit
of the models was evaluated with the
Hosmer-Lemeshow test, which we used
to compare the observed and expected
frequencies of the outcome (ie, necrosis
vs tumor) over the whole range of predic-
tions (22). Calculations were performed
by using the following computer pro-
grams: nonparametric ROC analysis ver-
sion 2.5 (23), SPSS for Windows (SPSS,
Chicago, Ill), and SAS (SAS, Cary, NC)
design library (FE Harrell, University of
Virginia, Charlottesville; available at
http://lib.stat.cmu.edu/S/Harrell/ ) for S-plus
(Mathsoft, Seattle, Wash).
RESULTS
Radiologic Characteristics
Table 2 shows the relationship of mass
size to the histologic findings at retroperi-
toneal resection. The size before chemo-
therapy, in contrast to the size after chemo-
therapy, was not clearly related to the
histologic findings in the residual mass.
Small residual masses contained necrosis
more often and contained cancer less
often when compared with larger masses.
Nearly half of the patients with very
small masses (0–9 mm, n 5 124) were
from Norway (Norwegian Radium Hospi-
tal, n 5 49). The reduction in size proved
to be a very strong predictor of necrosis at
resection: Seventy-five (80%) of 94 pa-
tients with a reduction of 85% or more
had only necrosis, whereas 99 (54%) of
184 patients with a decrease of 50%–69%
had necrosis. None of those with an
increased mass size had necrosis (Table 2).
Viable cancer was found in only three of
94 patients with a reduction in size of
85% or more. These three patients had
normal scans after chemotherapy; before
chemotherapy, their masses were 50, 48
and 25 mm.
Figure 2a–c illustrates the relationships
between the radiologic characteristics and
the probability of finding necrosis at resec-
tion. For size after chemotherapy, statisti-
cally significant nonlinearity was found
(P , .001). This finding indicated, for
example, that the likelihood of necrosis
differed more between a 10-mm mass and
a 20-mm mass than between a 50-mm
mass and a 60-mm mass. Use of the
square root of the size after chemother-
apy proved adequate, since the remain-
ing nonlinearity was nonsignificant (P 5
.10). Figure 2b, however, shows that this
transformation led to some overestima-
tion of the probability of necrosis for
mass sizes of 25–60 mm. The reduction in
size was approximately linearly related to
the probability of necrosis in a logistic
regression model; the nonlinearity, as de-
picted in Figure 2c, was statistically non-
significant (P 5 .11).
Clinical Characteristics
Table 3 shows the relationship of the
clinical characteristics to the histologic
findings at retroperitoneal resection. Ne-
crosis was more frequent when the pri-
mary tumor was teratoma-negative, when
the AFP or HCG levels were normal before
chemotherapy, or when the LDH level
was elevated before chemotherapy (all
P , .01). These four characteristics were
used to construct a simple score on the
basis of the number of favorable clinical
characteristics. This score was supported
by the multivariable odds ratios, which
were approximately 3.4, 3.1, 1.7, and 1.8.
The simple score ranged from 0 to 4 and
was clearly related to the probability of
necrosis (Table 3). However, viable cancer
was found in approximately 11% of the
patients without a clear relationship with
the score (Table 3). This implied that higher
scores predicted, in particular, the absence
of mature teratoma in the residual mass.
Combination of Radiologic and
Clinical Characteristics
Radiologic characteristics and clinical
characteristics were included in the logis-
tic regression models to evaluate their
ability to distinguish necrotic remnants
from residual tumor at resection. Figure 3
shows that the area under the ROC curve
was 0.737 (95% CI: 0.70, 0.78) when the
size of the mass after chemotherapy was
the only decision criterion. When the
reduction in size was also considered, the
ROC area increased to 0.771 (95% CI:
0.74, 0.80). This increase was especially
due to a better true-positive rate (resec-
tion of tumor) in the lower left corner in
Figure 3 where false-positive rates are low
(resection of necrosis). In this area, the
cutoff values for the residual mass size
TABLE 3
Clinical Characteristics and Histologic Findings at Resection
Characteristic
Necrosis
(n 5 302)
Teratoma
(n 5 268)
Cancer
(n 5 71)
Total
(N 5 641)
Histologic finding in primary tumor
Negative for teratoma 194 (63) 80 (26) 35 (11) 309
Positive for teratoma 108 (33) 188 (57) 36 (11) 332
Levels of markers before chemotherapy
AFP
Normal 140 (66) 55 (26) 17 (8) 212
Elevated 162 (38) 213 (50) 54 (13) 429
HCG
Normal 131 (58) 70 (31) 24 (11) 225
Elevated 171 (41) 198 (48) 47 (14) 416
LDH
Normal 67 (38) 97 (55) 13 (7) 177
Elevated 235 (51) 171 (37) 58 (13) 464
Simple score for necrosis
0 7 (15) 35 (75) 5 (11) 47
1 51 (27) 116 (62) 20 (11) 187
2 121 (50) 92 (38) 28 (12) 241
3 86 (69) 24 (19) 14 (11) 124
4 37 (88) 1 (2) 4 (10) 42
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were large (.30 mm), which indicated
that the reduction in size especially helped
in the improved distinction of necrosis
from malignancy in larger residual masses.
The area under the ROC curve in-
creased to 0.826 (95% CI: 0.80, 0.86)
when the simple clinical score was added
to the model. The simple clinical score
consisted of the following clinical charac-
teristics: teratoma-negative primary tu-
mor, normal prechemotherapy AFP level,
normal prechemotherapy HCG level, and
elevated prechemotherapy LDH level.
This extension of the model led to an
ROC curve that exceeded the previous
model (size and reduction) over the whole
range of mass sizes and reductions, includ-
ing small residual masses.
We noted that a true-positive rate of
100% was obtained only with a 100%
false-positive rate; hence, any selection of
patients for resection on the basis of the
radiologic and/or clinical characteristics
considered here missed some patients
with residual tumor. The improvements
from model 1 to model 2 and from model
2 to model 3 were statistically significant
(P , .01). According to our bootstrap
validation procedure, the overoptimism
in the estimation of the areas under the
ROC curves was trivial (eg, decrease from
0.826 to 0.823 for model 3). This finding
implied that the models were valid for
similar patients.
Table 4 shows the odds ratios of the
three logistic regression models. The odds
ratio for size after chemotherapy was
calculated so that it represented the com-
parison between a patient with a mass of
20 mm and a patient with a mass of 10
mm. The odds ratio in model 1 was 1.70,
which indicated that the odds of necrosis
was 1.70 times larger in the smaller mass.
This odds ratio was considerably smaller
in models 2 and 3, which included reduc-
tion in size, than in model 1 in which the
size after chemotherapy was considered
as the single predictor. This finding was
caused by correlation: In general, smaller
masses had a larger reduction (Pearson
correlation coefficient r 5 0.63). The
simple score for necrosis had a low corre-
lation with these radiologic characteris-
tics (r < 0.20). The odds ratios of the
radiologic characteristics were, hence, simi-
lar in models 2 and 3 (around 1.2 and 1.3).
In the third model, the clinical score
was the most important predictor (P ,
.001), followed by the reduction in size
(P , .001) and mass size after chemother-
apy, which was the least important (P 5
.01). The following equation can be used
to calculate the probability of necrosis:
score 5 22.365 2 (0.1514 · square root of
the size after chemotherapy) 1 (2.588 ·
reduction) 1 (0.8680 · simple score),
where the size is in millimeters, the reduc-
tion is expressed as a fraction, and the
simple score is expressed as points (0–4
points). The probability of necrosis was
1/(1 1 e2score).
The goodness of fit of the model that
included both radiologic and clinical char-
acteristics is illustrated in Table 5. We
focused on small residual masses (0–19
mm) in which resection decisions are
most subject to debate. Within small
masses, the reduction in size can be used
to reasonably distinguish patients with a
low risk of necrosis and patients with a
high risk of necrosis; the simple score for
necrosis further adds to this ability. The
observed frequencies reasonably concur
with the expected frequencies according
to the model, although the small number
of patients in some cells make compari-
sons difficult. Formal tests of goodness of
fit were statistically nonsignificant.
Finally, we prepared graphs to show the
predicted probabilities of necrosis in rela-
tion to radiologic and clinical characteris-
tics (Fig 4). When the simple score equals
0, the probability of necrosis is predicted
to be always less than 50%, even for the
most favorable combinations of mass sizes
before and after chemotherapy. For higher
Figure 3. Graph depicts the ROC curves for model 1 (size after
chemotherapy, dotted line), model 2 (size after chemotherapy and
reduction, dashed-and-dotted line) and model 3 (size after chemother-
apy, reduction in diameter, and clinical characteristics; solid line). For
model 1, combinations of true-positive (resection of tumor) and
false-positive (resection of necrosis) rates are marked according to the
cutoff values for the size of the residual mass. Best performance was
achieved with model 3.
TABLE 4
Odds Ratios and 95% CIs of the Three Logistic Regression Models
Characteristic
Model 1 Model 2 Model 3
Odds Ratio 95% CI Odds Ratio 95% CI Odds Ratio 95% CI
Size after chemotherapy* 1.70 1.52, 1.91 1.21 1.05, 1.40 1.22 1.04, 1.42
Reduction in size† · · · · · · 1.31 1.21, 1.41 1.30 1.19, 1.41
Simple score‡ · · · · · · · · · · · · 2.38 1.92, 2.96
* Square root transformation (comparison of a 10-mm mass with a 20-mm mass).
† Linear covariate (coded per 10%).
‡ Linear covariate (coded per point).
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scores (eg, scores of 3 or 4), the probabil-
ity of necrosis may well exceed 80% in
patients with a large reduction in mass
size. Nearly straight lines are shown in
Figure 4; this depiction is consistent with
the finding that a reduction in size was a
more important predictor of necrosis than
the residual mass size (P , .001 vs P 5
.01). We marked the areas where a clear
preference for resection (probability
,60%) or observation (probability .90%)
might be assumed.
DISCUSSION
These study findings show that simple,
readily-available clinical characteristics
significantly contribute to radiologic mea-
surements in the prediction of histologic
findings in a residual retroperitoneal mass
after chemotherapeutic treatment for
metastatic testicular cancer. Further, the
response to chemotherapy, expressed in
the reduction in size, is statistically more
important than the size after chemother-
apy. The combination of radiologic and
clinical characteristics more closely ap-
proximates the ideal definition of the two
subgroups—one with benign tissue only,
for which resection can be avoided, and a
second with residual cancer or mature
teratoma, for which resection is benefi-
cial.
The discriminative ability of the combi-
nation of reduction in mass size and size
after chemotherapy was signifcantly higher
than that of postchemotherapy size alone
(areas under the ROC curves of 0.74 and
0.77). Adding the four clinical characteris-
tics further improved the model (area
under the ROC curve of 0.83). These
characteristics included the histologic
findings in the primary tumor (presence
of teratoma elements) and the levels of
tumor markers AFP, HCG, and LDH be-
fore chemotherapy, which were com-
bined in a simple score based on the
number of favorable values. The predic-
tive value of these characteristics is well
documented (6–10).
A limitation of our analysis was that
many patients with masses of less than 10
mm after chemotherapy (normal CT scan)
did not undergo resection. Hence, the
histologic findings in their residual masses
remains unknown. Follow-up studies in
these patients might be valuable, specifi-
cally studies in which retroperitoneal re-
currence is examined, but these data are
currently not available to us. This selec-
tion poses no problem for the estimation
of regression coefficients once the size
after chemotherapy is correctly incorpo-
rated into the regression model that is
used to predict necrosis. Our analysis
indicated that a square root transforma-
tion of size after chemotherapy was ad-
equate. However, the selection causes veri-
fication bias, which has probably affected
the estimates of sensitivity and specificity
but not the estimates of the area under
the ROC curve (24,25). The latter esti-
mates proved to be very stable in an
evaluation of internal validity with boot-
strap techniques. A slightly more compli-
cated model showed adequate external
validity in a previous study (12). There-
fore, these findings imply that mass size
after chemotherapy should not be consid-
ered alone with regard to the likely histo-
logic content of a residual mass, but it
should be combined with the reduction
in size (comparison with the size before
chemotherapy) and clinical characteris-
tics. On the other hand, better predictors
of the histologic findings are needed to
bring the area under the ROC curve closer
to 1.
Several radiologic characteristics of re-
sidual masses have been related to the
histologic findings in residual masses, in
addition to mass size measurements. CT
parameters, such as attenuation (26,27)
and density (28), and magnetic reso-
nance (MR) imaging parameters (29) have
been studied but have been proved, in
general, not to be very informative. Also,
positron emission tomography (PET) has
been evaluated. The results at Indiana
University (30) were favorable: Although
PET could not be used to distinguish
between necrosis and mature teratoma,
masses in four patients that contained
cancer showed higher standardized up-
take values. These findings, however, were
not supported in another study (31).
Therefore, measurements of mass size are
currently the most relevant of radiologic
characteristics for the distinction of necro-
sis from malignancy.
A further limitation of our analysis was
the quality of the CT measurements avail-
able for statistical analysis. CT measure-
ments were not standardized over all
participating centers and merely reflected
TABLE 5
Goodness of Fit of Model 3 in 282 Patients with 0–19-mm Masses
after Chemotherapy
Simple Score
Reduction in Size (%)
0–49 50–69 70–84 $85 Total
0
Expected frequency* (%) 8 (5, 14) 20 (14, 29) 32 (23, 43) 43 (31, 56) 21 (15, 30)
Observed frequency† (%) · · · (n 5 4) · · · (n 5 6) · · · (n 5 3) · · · (n 5 3) 28 (n 5 18)
No. of patients with
findings at resection‡ 0/4/0 2/4/0 2/1/0 1/2/0 5/13/0
1
Expected frequency* (%) 23 (17, 31) 39 (32, 46) 52 (44, 60) 65 (56, 73) 47 (40, 55)
Observed frequency† (%) · · · (n 5 8) 48 (n 5 23) 64 (n 5 22) 63 (n 5 19) 53 (n 5 73)
No. of patients with
findings at resection‡ 2/5/1 11/11/1 14/8/0 12/6/1 39/31/3
2
Expected frequency* (%) 38 (30, 47) 60 (54, 65) 71 (66, 77) 81 (75, 86) 65 (59, 71)
Observed frequency† (%) 57 (n 5 21) 68 (n 5 28) 58 (n 5 24) 86 (n 5 35) 69 (n 5 108)
No. of patients with
findings at resection‡ 12/9/0 19/8/1 14/8/2 30/5/0 75/30/3
3
Expected frequency* (%) 68 (60, 75) 78 (71, 83) 85 (80, 89) 92 (88, 95) 85 (80, 89)
Observed frequency† (%) · · · (n 5 2) 88 (n 5 16) 67 (n 5 15) 86 (n 5 23) 82 (n 5 55)
No. of patients with
findings at resection‡ 2/0/0 14/2/0 10/3/2 19/2/1 45/7/3
4
Expected frequency* (%) 70 (54, 82) 90 (84, 94) 94 (89, 96) 96 (93, 98) 92 (87, 95)
Observed frequency† (%) · · · (n 5 2) · · · (n 5 7) · · · (n 5 8) 91 (n 5 11) 89 (n 5 28)
No. of patients with
findings at resection‡ 1/0/1 6/0/1 8/0/0 10/0/1 25/0/3
Total
Expected frequency* (%) 35 (27, 43) 57 (51, 63) 69 (63, 75) 81 (75, 86) 64 (58, 70)
Observed frequency† (%) 46 (n 5 37) 65 (n 5 80) 67 (n 5 72) 80 (n 5 90) 67 (N 5 282)
No. of patients with
findings at resection‡ 17/18/2 52/25/3 48/20/4 72/15/3 189/81/12
* Frequency of necrosis. Numbers in parentheses are 95% CIs.
† Frequency of necrosis. Data are shown if n $ 10.
‡ Findings are no. of patients with necrosis/no. of patients with mature teratoma/no. of patients
with cancer.
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a routine-care situation. The level of ex-
pertise and, hence, the accuracy of the
measurements may have differed among
the radiologists. Also, current CT scan-
ners provide measurements that are more
precise than those possible with the equip-
ment used in the 1980s (32). Therefore,
the predictive ability of current CT mea-
surements may be better than that shown
in our evaluation.
When new radiologic characteristics
are evaluated, we advocate that adjust-
ments be made for mass size and clinical
characteristics, as defined in the present
study. This can be achieved, for example,
with an evaluation of the new characteris-
tic in a logistic regression model that
includes the result from the formula for
model 3 as a simple linear covariate.
Further, we hope that new histologic,
molecular, or genetic markers that can be
used to predict the histologic findings in
the residual mass will be identified. Again,
evaluation of such markers should ac-
count for the simple predictive character-
istics considered in the present study.
In the absence of stronger predictors,
decisions regarding resection have to be
made. Resection policies vary widely be-
tween centers, especially for small re-
sidual masses (6–9). Part of this variation
may be justified by local circumstances,
such as the feasibility of frequent fol-
low-up with high-quality CT scanning
when resection is not performed (9).
Other possible reasons for this variation
include different appraisals of the conse-
quences of leaving mature teratoma or
cancer unresected and insufficient knowl-
edge of the prevalence of residual malig-
nancy in (very) small masses. The latter
may be resolved by our ‘‘evidence graphs’’
(Fig 4), which may be useful in the com-
munication between the radiologist and
the treating physicians (urologic surgeon
and medical oncologist).
In a previous evaluation, we compared
several resection policies (33). The results
of this comparison showed that resection
is not considered to be indicated when
the probability of necrosis exceeds 90%.
For this subgroup, it may well be argued
that the risks of short-term and long-term
morbidity are not balanced by the poten-
tial benefits of resection, which include
prevention of growth of mature tera-
toma, complete resection of viable tumor,
and administration of additional chemo-
therapeutic treatments after resection of
viable cancer (34).
These benefits likely outweigh the risks
of resection in patients with a probability
of less than 60%. This group contains
patients with masses that enlarge despite
chemotherapy. We identified 51 of such
patients in our data set: Forty-four (86%)
had mature teratoma, and seven (14%)
cancer. These findings confirmed those of
earlier reports (35). The optimal treat-
ment in patients with probabilities be-
tween 60% and 90% is debatable. A cutoff
of 70% or 80% may be considered, but
individual assessment of the patient’s con-
dition and his or her preferences are
important. Also, in general, resection of
small residual masses will not lead to
long-term morbidity such as retrograde
ejaculation; this consideration supports
resection of small masses.
In conclusion, decisions regarding re-
section of residual masses should not be
based on only the size of the mass after
chemotherapy. The scan obtained before
chemotherapy should be considered to
determine the reduction in size, which
should be combined with readily avail-
able clinical characteristics. This evidence-
based approach will optimize the deci-
sions in the patient’s interest.
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